Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Buse, J. B.
Right arrow Articles by Whitcomb, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buse, J. B.
Right arrow Articles by Whitcomb, R. W.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 21, Issue 9 1455-1461, Copyright © 1998 by American Diabetes Association

ARTICLES

Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group

JB Buse, B Gumbiner, NP Mathias, DM Nelson, BW Faja and RW Whitcomb
Department of Medicine, Diabetes Care Center, University of North Carolina, Chapel Hill, USA.

OBJECTIVE: To determine the ability of troglitazone to reduce requirements for injected insulin while maintaining blood glucose levels in insulin-treated patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: This 26-week double-blind study with open-label extension included patients who had failed previous oral antidiabetic medication and took > or =30 but <150 U of insulin daily The 222 patients in the double-blind study received 200 or 400 mg troglitazone once daily or matching placebo. The primary end point was the proportion of patients meeting the target of > or =50% reduction in injected insulin and either a 15% reduction in fasting blood glucose or a blood glucose <7.8 mmol/l. Insulin dose was reduced 25% based on a study-specific algorithm whenever fasting blood glucose was reduced 5% from baseline. Also of interest were changes in insulin dose and HbA1c. The open-label extension included 173 patients. They received 200 mg of troglitazone with optional titration to 400 mg, and insulin dose was adjusted based on investigators' standards of care. Open-label measures were change in insulin dose, HbA1c, and fasting serum glucose (FSG). RESULTS: In the double-blind phase, 22 and 27% of the 200- and 400-mg troglitazone groups, respectively, reached target, compared with placebo (7%) (P < 0.01). Insulin dose reductions of 13 +/- 3, 30 +/- 3, and 41 +/- 3 U were observed for placebo, 200-, and 400-mg troglitazone groups, respectively HbA1c decreased 0.09 +/- 0.14% for placebo, 0.13 +/- 0.14% for 200 mg, and 0.41 +/- 0.14% for 400 mg (P < 0.05) troglitazone. In the open-label extension, troglitazone treatment resulted in >50% reduction from baseline in daily insulin dose and decreases in HbA1c of 1% and in FSG of >17%. CONCLUSIONS: Troglitazone decreases daily injected insulin dose requirements and improves glycemic control in insulin-treated patients with type 2 diabetes.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
P. Hollander, D. Yu, and H. S. Chou
Low-Dose Rosiglitazone in Patients With Insulin-Requiring Type 2 Diabetes
Arch Intern Med, June 25, 2007; 167(12): 1284 - 1290.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
S. M. Strowig and P. Raskin
The Effect of Rosiglitazone on Overweight Subjects With Type 1 Diabetes
Diabetes Care, July 1, 2005; 28(7): 1562 - 1567.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
S. M. Strowig, M. L. Aviles-Santa, and P. Raskin
Improved Glycemic Control Without Weight Gain Using Triple Therapy in Type 2 Diabetes
Diabetes Care, July 1, 2004; 27(7): 1577 - 1583.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. U Kabadi and U. M Kabadi
Efficacy of Sulfonylureas with Insulin in Type 2 Diabetes Mellitus
Ann. Pharmacother., November 1, 2003; 37(11): 1572 - 1576.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin. Proc.Home page
J. L. Chan and M. J. Abrahamson
Pharmacological Management of Type 2 Diabetes Mellitus: Rationale for Rational Use of Insulin
Mayo Clin. Proc., April 1, 2003; 78(4): 459 - 467.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
S. M. Strowig, M. L. Aviles-Santa, and P. Raskin
Comparison of Insulin Monotherapy and Combination Therapy With Insulin and Metformin or Insulin and Troglitazone in Type 2 Diabetes
Diabetes Care, October 1, 2002; 25(10): 1691 - 1698.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring
Pathophysiology and Pharmacological Treatment of Insulin Resistance
Endocr. Rev., December 1, 2000; 21(6): 585 - 618.
[Abstract] [Full Text]

Home page
 ANN INTERN MEDHome page
R. A. DeFronzo
Pharmacologic Therapy for Type 2 Diabetes Mellitus
Ann Intern Med, August 17, 1999; 131(4): 281 - 303.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
D. Altkorn, K. Roach, S. Stern, and W. Levinson
Update in General Internal Medicine
Ann Intern Med, August 3, 1999; 131(3): 199 - 206.
[Full Text] [PDF]

Home page
 JWatch GeneralHome page
Troglitazone for Type 2 Diabetes
Journal Watch (General), September 11, 1998; 1998(911): 4 - 4.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1998 by the American Diabetes Association.